<DOC>
	<DOC>NCT01520727</DOC>
	<brief_summary>The purpose of this study was to investigate the safety, tolerability, pharmacokinetics and catechol-O-methyltransferase (COMT) activity of BIA 9-1067 in healthy male subjects after single oral ascending doses.</brief_summary>
	<brief_title>A Single Oral Ascending Dose Study of BIA 9-1067 in Healthy Male Subjects</brief_title>
	<detailed_description>Single centre, randomised, double-blind, placebo-controlled study of single ascending doses in up to 8 sequential groups of 8 healthy young male subjects.</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Opicapone</mesh_term>
	<criteria>A signed and dated informed consent form before any studyspecific screening procedure was performed. Aged between 18 and 45 years, inclusive. Healthy as determined by the investigator on the basis of medical history, physical examination, clinical laboratory test results, vital signs and digital 12lead ECG. Nonsmoker or smoker of fewer than 10 cigarettes per day as determined by history. Must be able to abstain from smoking during the inpatient stay. Any significant cardiovascular (e.g. hypertension), hepatic, renal, respiratory (e.g. childhood asthma), gastrointestinal, endocrine (e.g. diabetes, dyslipidemia), immunologic, dermatological, haematological, neurologic, or psychiatric disease. Acute disease state (e.g., nausea, vomiting, fever, diarrhoea) within 7 days before study day 1. History of drug abuse within 1 year before study day 1. History of alcoholism within 1 year before day 1. Consumption of more than 50 g of ethanol per day (12.5 cL glass of 10° [10%] wine = 12 g; 4 cL of aperitif, 42° [42%] whiskey = 17 g; 25 cL glass of 3° [3%] beer = 7.5 g; 25 cL glass of 6° [6%] beer = 15 g Positive serologic findings for human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen (HBsAg), and/or hepatitis C virus (HCV) antibodies. Positive findings of urine drug screen (eg, amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, methadone, opiates, MDMA [3,4methylenedioxymethamphetamine; ecstasy]). History of any clinically important drug allergy. Prohibited Treatments: use of any investigational drug within 90 days or prescription drug within 30 days before investigational medical product (IMP) administration. Consumption of any caffeinecontaining products (e.g., coffee, tea, chocolate, or soda) in excess of 6 cups per day (or equivalent), of grapefruit, grapefruitcontaining products, or alcoholic beverages within 24 hours before study day 1. Use of any overthecounter drugs including herbal supplements (except for the occasional use of acetaminophen [paracetamol], aspirin and vitamins ≤100% recommended daily allowance) within 7 days before IMP administration. Donation of blood (i.e. 450 mL) within 60 days before study day 1</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>BIA 9-1067</keyword>
</DOC>